Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CFRXNASDAQ:GLMDNASDAQ:ONCRNASDAQ:OTIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsGLMDGalmed Pharmaceuticals$1.43+5.1%$1.40$1.15▼$23.80$2.37M0.491.30 million shs196,888 shsONCROncorus$0.13$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,947 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%GLMDGalmed Pharmaceuticals+5.15%+1.42%+4.38%-34.22%-67.14%ONCROncorus0.00%0.00%0.00%0.00%0.00%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals1.4395 of 5 stars0.04.00.00.02.52.50.6ONCROncorusN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCFRXContraFect 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/AONCROncorus 0.00N/AN/AN/AOTICOtonomy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, ONCR, CFRX, and GLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/AONCROncorusN/AN/AN/AN/A$2.33 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AGLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%N/AONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest OTIC, ONCR, CFRX, and GLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCFRXContraFectN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCFRXContraFectN/A0.530.53GLMDGalmed PharmaceuticalsN/A7.037.03ONCROncorusN/AN/AN/AOTICOtonomyN/A1.741.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCFRXContraFect7.85%GLMDGalmed Pharmaceuticals76.14%ONCROncorus20.07%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipCFRXContraFect0.62%GLMDGalmed Pharmaceuticals19.80%ONCROncorus17.10%OTICOtonomy1.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionableONCROncorus6426.09 million21.63 millionOptionableOTICOtonomy5168.53 million67.78 millionOptionableOTIC, ONCR, CFRX, and GLMD HeadlinesRecent News About These CompaniesOtonomy's hearing loss drug shows no benefit in trial, tanking sharesSeptember 3, 2024 | pharmaphorum.comTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023April 21, 2024 | straight.comAllergic Contact Dermatitis and Topical AntibioticsSeptember 10, 2023 | medscape.comHearing Loss in AdultsAugust 21, 2023 | nejm.orgResearch PublicationsAugust 4, 2023 | slu.eduManagement of Pediatric Otitis MediaMay 11, 2023 | medscape.comHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRMay 8, 2023 | news.google.comAlluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaApril 28, 2023 | news.google.comVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalApril 27, 2023 | news.google.comHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRApril 25, 2023 | news.google.comENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalApril 24, 2023 | news.google.comHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalApril 11, 2023 | news.google.comENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalApril 10, 2023 | news.google.com[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital JournalApril 10, 2023 | news.google.comHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalApril 3, 2023 | news.google.comHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints NewsMarch 30, 2023 | news.google.comAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsMarch 30, 2023 | news.google.comMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints NewsMarch 30, 2023 | news.google.comBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsMarch 30, 2023 | news.google.comSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints NewsMarch 30, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveBy Nathan Reiff | May 23, 2025View NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?OTIC, ONCR, CFRX, and GLMD Company DescriptionsContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Galmed Pharmaceuticals NASDAQ:GLMD$1.43 +0.07 (+5.15%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.43 0.00 (0.00%) As of 05/29/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Oncorus NASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
